Generate Biomedicines Inc... (GENB)
Generate Biomedicines Inc. (GENB) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | 11.72 |
| Marktkapitalisierung | 2.18 Mrd |
| Umsatz (TTM) | 26.48 Mio |
| Nettogewinn (TTM) | -268.67 Mio |
| Beta | n/a |
| EPS (ttm) | -2.1 |
| KGV (TTM) | n/a |
| Forward-KGV | -7.44 |
| KBV (TTM) | 4.77 |
| KUV (TTM) | 82.25 |
| Earnings Date | Nov 5, 2026 |
| Brief | 20.21 |
| Volumen | 576,225 |
| Ø Vol. (20D) | 805,754 |
| Eröffnung | 15.68 |
| Vortagesschluss | 15.69 |
| Tagesspanne | 15.64 - 16.63 |
| 52-Wk Range | 11.00 - 18.18 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über GENB
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an ...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Generate Biomedicines 31.89 Mio, ein Anstieg von 55.89% im Vergleich zum Vorjahr (20.46 Mio). Der Gewinn lag bei -203.15 Mio, ein Anstieg von 16.91 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 2 Wochen · The Wall Street Journal
Jersey Mike’s Is the Latest Stock Slide in Trading Debuts This YearJersey Mike’s Subs, with its 5.96% stock-price decline Thursday, is hardly alone in having a first-day share slide. This year, shares for hedge fund Pershing Square, nuclear fuel company Standard Nucl...
